Cited by 54Computational Drug Discovery MethodsProtein Interaction Studies and Fluorescence AnalysisMachine Learning in Bioinformatics

Proteochemometrics – recent developments in bioactivity and selectivity modeling

Open access
Bongers, Brandon J., IJzerman, Adriaan. P., Van Westen, Gerard J.P.·2019·Drug Discovery Today: Technologies

Abstract

Proteochemometrics is a machine learning based modeling approach relying on a combination of ligand and protein descriptors. With ongoing developments in machine learning and increases in public data the technique is more frequently applied in early drug discovery, typically in ligand-target binding prediction. Common applications include improvements to single target quantitative structure-activity relationship models, protein selectivity and promiscuity modeling, and large-scale deep learning approaches. The increase in predictive power using proteochemometrics is observed in multi-target bioactivity modeling, opening the door to more extensive studies covering whole protein families. On top of that, with deep learning fueling more complex and larger scale models, proteochemometrics allows faster and higher quality computational models supporting the design, make, test cycle.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ddtec.2020.08.003

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recent efforts have broadened applicability of supervised AI/ML models to low-data and no-data scenarios, i.e., under-studied and unliganded proteins.

    “Indeed, recent efforts have broadened the applicability of supervised AI/ML models to low-data and no-data scenarios,112,113 i.e. to under-studied and unliganded proteins.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 53 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. Yordanov V, Dimitrov I, Doytchinova I. Proteochemometric analysis of peptides binding to human leukocyte antigen (Hla) proteins from locus Dp, vol. 64. 2017.

Cited by

Sorted by citations

Authors
Bongers, B. J., IJzerman, A. P., & Van Westen, G. J. P.
Affiliations
Leiden University (NL)
Venue
Drug Discovery Today: Technologies
Publisher
Elsevier BV
Published
2019-12
Volume
32-33
Pages
89-98
ISSN
1740-6749 (ISSN-L)
OpenAlex
W3087418839
Cited by
54
References
53
Citations by year
2026: 5 · 2025: 6 · 2024: 16 · 2023: 14 · 2022: 5 · 2021: 7 · 2019: 1
FWCI
0.27
Type
journal article
Language
en
Open access
Locations
  • Drug Discovery Today Technologies (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by)
Topics
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Machine Learning in Bioinformatics
Keywords
proteochemometrics, protein selectivity, QSAR, deep learning, early drug discovery, ligand descriptors, protein descriptors
MeSH terms
Binding Sites, Humans, Ligands, Models, Molecular, Proteins, Quantitative Structure-Activity Relationship, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review